The DOI matches its Crossref record, with a small difference in title or year; 36 of the 36 references it cites were found in a registry or an index.
Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry
Abstract
Background—: Despite the known association of diabetes mellitus with cardiovascular events, there are few contemporary data on the long-term outcomes from international cohorts of patients with diabetes mellitus. We sought to describe cardiovascular outcomes at 4 years and to identify predictors of these events in patients with diabetes mellitus. Methods and Results—: The Reduction of Atherothrombosis for Continued Health (REACH) registry is an international registry of patients at high risk of atherothrombosis or established atherothrombosis. Four-year event rates in patients with diabetes mellitus were determined with the corrected group prognosis method. Of the 45 227 patients in the REACH registry who had follow-up at 4 years, 43.6% (n=19 699) had diabetes mellitus at baseline. The overall risk and hazard ratio (HR) of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke were greater in patients with diabetes compared with patients without diabetes (16.5% versus 13.1%; adjusted HR, 1.27; 95% confidence interval [CI] 1.19–1.35). There was also an increase in both cardiovascular death (8.9% versus 6.0%; adjusted HR, 1.38; 95% CI, 1.26–1.52) and overall death (14.3% versus 9.9%; adjusted HR, 1.40; 95% CI, 1.30–1.51). Diabetes mellitus was associated with a 33% greater risk of hospitalization for heart failure (9.4% versus 5.9%; adjusted odds ratio, 1.33; 95% CI, 1.18–1.50). In patients with diabetes mellitus, heart failure at baseline was independently associated with cardiovascular death (adjusted HR, 2.45; 95% CI, 2.17–2.77; P <0.001) and hospitalization for heart failure (adjusted odds ratio, 4.72; 95% CI, 4.22–5.29; P <0.001). Conclusions—: Diabetes mellitus substantially increases the risk of death, ischemic events, and heart failure. Patients with both diabetes mellitus and heart failure are at particularly elevated risk of cardiovascular death, highlighting the need for additional therapies in this high-risk population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The observed annualized primary endpoint event rate for placebo patients in REDUCE-IT was 5.74%, which is consistent with historical cardiovascular outcome studies, including those published since the design of REDUCE-IT, with comparable patient populations and expanded or hard major adverse cardiovascular events (MACE) (4,8,9,30-44).”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [4]
In the citing paper
“Patients with T2DM are at high risk for ASCVD and HF compared with nondiabetic individuals (50,53).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [53]
In the citing paper
“Recent studies have found that rates of incident heart failure hospitalization (adjusted for age and sex) were twofold higher in people with diabetes compared with those without (5,6).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,385
Statistical Analysis with Missing Data
Little, R. J. A., & Rubin, D. B. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/9781119013563 · Cited by 8,473
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Heart Disease and Stroke Statistics—2014 Update
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,264
Danaei, G., Finucane, M. M., Lu, Y., Singh, G. M., Cowan, M. J., Paciorek, C. J., Lin, J. K., Farzadfar, F., Khang, Y.-H., Stevens, G. A., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60679-x · Cited by 3,568
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440
Changes in diabetes-related complications in the United States, 1990-2010
Gregg, E. W., Li, Y., Wang, J., Rios Burrows, N., Ali, M. K., Rolka, D., Williams, D. E., & Geiss, L. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310799 · Cited by 1,749
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1001/jama.1988.03410230074031 · DOI
Cited by
Sorted by citations
Items 301–400 of 500
Chen, A. C.-C., Huang, K.-L., Chen, H.-M., Chen, P.-C., Chen, V. C.-H., & Chiu, W.-C. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.06.078 · Cited by 6
del Val, D., Berta, B., Roleder, T., Malinowski, K. P., Bastante, T., Hermanides, R. S., Wojakowski, W., Fabris, E., Cuesta, J., Luca, G. D., et al. (2024) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeae210 · Cited by 6
Yu, J.-M., Chen, W., Shia, B., & Wu, S. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03488-2 · Cited by 6
Nishikawa, K., Ohta, R., & Sano, C. (2024) · BMC Family Practice · doi:10.1186/s12875-024-02558-3 · Cited by 6
Design, Synthesis and SAR Studies of Novel and Potent Dipeptidyl Peptidase 4 Inhibitors
Luo, N., Fang, X., Su, M., Zhang, X., Li, D., Li, H., Li, S., & Zhao, Z. (2020) · Chinese Journal of Chemistry · doi:10.1002/cjoc.202000342 · Cited by 6
Nørgaard, C. H., Starkopf, L., Gerds, T. A., Malmborg, M. W., Bonde, A. N., Zareini, B., Mills, E. H. A., Vestergaard, P., Wong, N. D., Torp-Pedersen, C. T., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108126 · Cited by 5
Diabetes mellitus and heart failure — a modern look at the mechanisms of development
Svarovskaya, A. V., & Анатольевна, Г. А. (2022) · Diabetes Mellitus · doi:10.14341/dm12648 · Cited by 6
Inggriani, M. P., Musthafa, A., Puspitawati, I., Fachiroh, J., Dewi, F. S. T., & Hartopo, A. B. (2022) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2022-0011 · Cited by 6
Yu, J.-M., Chen, W., Chen, M., Shia, B., & Wu, S. (2023) · Pharmaceuticals · doi:10.3390/ph16040507 · Cited by 6
Bashier, A. M., Farghaly, M., Ali, J. A., Alhadari, A. K., Ajaz, Y., Warrier, V. K., Abdelgadir, E., Farooqi, M. H., Qamar, S., Alsayed, M., et al. (2023) · Dubai Diabetes and Endocrinology Journal · doi:10.1159/000530467 · Cited by 6
Kim, H., Kang, D., Ahn, J.-M., Lee, J., Choi, Y., Hur, S., Park, H.-J., Tresukosol, D., Kang, W.-C., Kwon, H.-M., et al. (2023) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2023.07.028 · Cited by 5
Shakour, N., Hoseinpoor, S., Rajabian, F., Azimi, S. G., Iranshahi, M., Sadeghi‐Aliabadi, H., & Hadizadeh, F. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2298734 · Cited by 6
Halon, D. A., Jubran, A., Rubinshtein, R., Zafrir, B., Azencot, M., & Lewis, B. S. (2017) · Cardiology · doi:10.1159/000478995 · Cited by 6
Kobalava, Z. D., & Kiyakbaev, G. (2018) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2018-8-79-91 · Cited by 7
Mason, R. P., Dawoud, H., Sherratt, S. C. R., Wagner, M. R., & Maliñski, T. (2019) · American Journal of Pharmacology and Toxicology · doi:10.3844/ajptsp.2019.7.16 · Cited by 6
Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease
Wu, B. Y., & Shi, L. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa082 · Cited by 6
Practical Considerations and Opportunities for SGLT2 Inhibitor Prescription in Heart Failure
Faulkenberg, K. D., Williams, J. B., Isaacs, D. M., & West, L. M. (2020) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-020-00825-x · Cited by 6
Wang, H., Cai, Z., Yin, D., Yang, Y., Song, W., & Dou, K.-F. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.11.043 · Cited by 6
Wang, H., Cai, Z., Yin, D., Song, W., Feng, L., Gao, R.-L., Yang, Y., & Dou, K. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.586491 · Cited by 7
Kerola, A. M., Juonala, M., & Kytö, V. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112411 · Cited by 6
Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults
Hennessy, S. S., Penko, J. M., Bellows, B. K., Coxson, P. G., Boylan, R. D., Sims, K. D., Beatty, A. L., Inoue, K., Shi, I., Decker, S. R. D. R., et al. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2025.5243 · Cited by 5
Bauduceau, B., Bordier, L., Bringer, J., Chabrier, G., Charbonnel, B. H., Cosson, E., Darmon, P., Detournay, B., Fontaine, P., Gourdy, P., et al. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30056-2 · Cited by 7
Positionspapier Herzinsuffizienz und Diabetes
Schütt, K. S., Aberle, J., Bauersachs, J. K., Birkenfeld, A. L., Frantz, S., Ganz, M., Jacob, S., Kellerer, M., Leschke, M., Liebetrau, C., et al. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1867-3026 · Cited by 5
Farah, C., Adla, Y. A., & Awad, M. (2022) · IEEE Mediterranean Electrotechnical Conference (MELECON) · doi:10.1109/melecon53508.2022.9842984 · Cited by 5
Cheng, Q., Zou, S., Feng, C., Xu, C., Zhao, Y., Shi, X., & Sun, M. (2023) · Medicine · doi:10.1097/md.0000000000033198 · Cited by 5
Rational choice of therapy in patients with diabetes mellitus type 2 with concomitant gout
Паневин, Т. С., Салухов, В. В., & Михайловна, Р. Д. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-153 · Cited by 5
Cortés, M., Lorenzo, Ó., Lumpuy‐Castillo, J., Martínez-Albaladejo, S., Urquía, M. T., Pello, A. M., Becerra, A. J. B., Orejas, M., Navas, M. Á., Macia, E., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206698 · Cited by 5
Kobo, O. M., Cavender, M. A., Jensen, T., Kuhlman, A. B., Rasmussen, S., & Verma, S. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15396 · Cited by 5
Self-citationBorges, R. D. S., Almeida, G. D. O., Alves, V. F. C., Nienkotter, T. F., Bertoli, E. D., & Silva, A. C. S. E. (2023) · Journal of Nephrology · doi:10.1007/s40620-023-01818-2 · Cited by 5
Kelsey, M. D., Ford, C. B., Oakes, M. M., Soneji, S. S., Bosworth, H. B., & Pagidipati, N. J. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.47102 · Cited by 5
In vitro validation of measurement of volume elastic modulus using photoplethysmography
Njoum, H., & Kyriacou, P. A. (2017) · Medical Engineering & Physics · doi:10.1016/j.medengphy.2017.11.011 · Cited by 5
Arnold, S. V., Jones, P. G., Beasley, M., Cordova, J. M., Goyal, A., Fonarow, G. C., & SEMAN, L. J. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01190-6 · Cited by 5
Guo, R., Wang, X., Liu, Y., Huang, M., Ma, M., He, Y., Yang, R., Gao, S., Luo, M., Zhao, G., et al. (2023) · Angiology · doi:10.1177/00033197231198688 · Cited by 5
Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes
Gerstein, H. C., & Shah, R. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.003 · Cited by 6
The cost of cardiovascular-disease-related death in patients with type 2 diabetes mellitus
Shetty, S. S., Stafkey-Mailey, D., Yue, B., Coutinho, A. D., Wang, W., Parigi, A. D., Sander, S. D., & Coleman, C. I. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1445620 · Cited by 5
Šuran, D., Kanič, V., Naji, F. H., Krajnc, I., Čokolič, M., Zemljič, E., & Sinkovič, A. (2019) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2019.4250 · Cited by 5
Wang, X., Chen, H., Essien, E. J., Wu, J., Serna, O., Paranjpe, R., & Abughosh, S. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00395-0 · Cited by 6
Jindal, A., Tomar, D., Anshika, Mainuddin, Kumar, A., & Pal, S. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44665-8.00027-4 · Cited by 4
Role of Sodium-Glucose Cotransporter-2 Inhibition in the Treatment of Adults With Heart Failure
Sharma, A., & Ezekowitz, J. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.08.012 · Cited by 4
Formica, F., Gallingani, A., Tuttolomondo, D., Hernández‐Vaquero, D., D’Alessandro, S., Singh, G., Grassa, G., Pattuzzi, C., & Nicolini, F. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102135 · Cited by 4
Sinha, T., Gul, U., Babar, N. N., Israr, F., Butt, A. A., Chaudhari, S. S., Maqbool, H., & Amin, A. (2024) · Cureus · doi:10.7759/cureus.69711 · Cited by 4
Cardiovascular events in patients with over 10 years history of type 2 diabetes mellitus
Saed, L., Deihim, Z., Naghshbandi, M. K., Rajabnia, M., & Naleini, S. N. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.08.026 · Cited by 4
Verma, S., Eikelboom, J. W., Al-Omran, M. A., Choi, R., Heffernan, M., Teoh, H., & Bhatt, D. L. (2020) · Med · doi:10.1016/j.medj.2020.05.003 · Cited by 4
Self-citationOmair, M., Koshy, A. N., Dinh, D. T., Brennan, A., Reid, C. M., Ajani, A. E., Duffy, S. J., Farouque, O., Yudi, M., & Clark, D. J. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.11.036 · Cited by 4
Mandal, N. A., Asuzu, P., Stentz, F. B., Wan, J. Y., & Dagogo-Jack, S. E. (2023) · Experimental Biology and Medicine · doi:10.1177/15353702231184228 · Cited by 4
Yang, C. D., Chen, J. W., Quan, J. W., Shu, X. Y., Feng, S., Aihemaiti, M., Ding, F. H., Shen, W. F., Lu, L., Zhang, R., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1211954 · Cited by 4
Oral Antidiabetic Agents and Cardiovascular Outcomes
Pareek, M., & Bhatt, D. L. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.07.003 · Cited by 4
Self-citationSharma, A., Butler, J., Zieroth, S. R., Giannetti, N., & Verma, S. (2019) · Diabetic Medicine · doi:10.1111/dme.14140 · Cited by 4
Cardiovascular Risk Reduction With Icosapent Ethyl: A Systematic Literature Review
Thakur, M., Sangha, P. S., Satti, A., & Shah, P. (2020) · Cureus · doi:10.7759/cureus.10942 · Cited by 4
Diabetic Cardiomyopathy: Clinical and Metabolic Approach
Djordjevic, D. B., Koracevic, G. P., Djordjević, A., & Lović, D. B. (2020) · Current Vascular Pharmacology · doi:10.2174/1570161119999201102213214 · Cited by 3
SGLT2 Inhibitors: Emerging Opportunities for the Treatment of Myocardial Infarction
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_4 · Cited by 4
Alrasheed, R., Altaf, A. F., Althurwi, A. H., Alrodan, S. F., Asiri, M. H., Alsaluli, B. A., Alsurur, M., Alghamdi, K. A., Alrowaithi, A. A., & Almalki, N. S. (2025) · Medicina · doi:10.3390/medicina62010069 · Cited by 3
Knigge, P., Lundberg, S., Strange, J. E., Malik, M. E., Nouhravesh, N., Wagner, A. K., Gislason, G., Fosbøl, E. L., Carlson, N., Zahir, D., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032539 · Cited by 3
Huang, H., Li, Y., Chen, Y., & Fu, G. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.194663 · Cited by 3
Sex Differences in the Mortality Risk of Elderly Patients with Systolic Heart Failure in Taiwan.
Wu, T.-J., Lin, G., Lin, C., Liu, P., Su, K.-J., Lin, C.-C., Lin, T.-C., Cheng, S., Lin, S.-H., Takimoto, E., et al. (2020) · PubMed Central · doi:10.6515/acs.202011_36(6).20200512a · Cited by 3
Kalashnikov, V. Y., & Michurova, M. S. (2021) · Kardiologiia · doi:10.18087/cardio.2021.1.n1148 · Cited by 3
Shi, D., Wang, L., & Cong, H. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2306190 · Cited by 4
Positionspapier Herzinsuffizienz und Diabetes
Schütt, K. S., Aberle, J., Bauersachs, J. K., Birkenfeld, A. L., Frantz, S., Ganz, M., Jacob, S., Kellerer, M., Leschke, M., Liebetrau, C., et al. (2022) · Die Kardiologie · doi:10.1007/s12181-022-00562-4 · Cited by 3
Piotrowicz, E., Pencina, M. J., Kowalik, I., Orzechowski, P., Banach, M., Główczyńska, R., Zaręba, W., Opolski, G., Szalewska, D., Pluta, S., et al. (2023) · Kardiologia Polska · doi:10.33963/kp.a2023.0116 · Cited by 3
Janjani, P., Salehabadi, Y., Motevaseli, S., Moghadam, R. H., Siabani, S., & Salehi, N. (2023) · Salmand · doi:10.32598/sija.2022.3091.2 · Cited by 3
Hao, W., Wang, B., Fan, J., Que, B., Ai, H., Wang, X., & Nie, S. (2023) · Sleep Medicine · doi:10.1016/j.sleep.2023.10.009 · Cited by 4
Romero, A., Saldarriaga, C., Ramos, C. E., Quesada, D., Chazzin, G., Fernández, F. N. G., Pow-Chon-Long, F., Alarco, W., Hurtado, P. E., Magaña, J. A., et al. (2023) · Archivos de cardiología de México · doi:10.24875/acm.23000059 · Cited by 3
Sun, R., Jia, J., Wang, S., Wang, Z., Wang, C., Xu, Y., & Yang, Y. (2024) · Endocrine · doi:10.1007/s12020-023-03669-0 · Cited by 3
Yamamoto, K., Shiomi, H., Morimoto, T., Miyazawa, A., Nakamura, S., Suwa, S., Fujita, T., Kurita, T., Sugawara, S., Fujii, K., et al. (2024) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2024.04.054 · Cited by 3
Risk Factors for Atherosclerotic Cardiovascular Disease
Weidner, C., & Braun, L. T. (2024) · Springer eBooks · doi:10.1007/978-3-031-53705-9_4 · Cited by 3
Modelling Adverse Events in Patients Receiving Chronic Oral Corticosteroids in the UK
Gibson, D., Branscombe, N., Martin, N., Menzies-Gow, A. N., Jain, P., Padgett, K., & Yeates, F. (2024) · PharmacoEconomics - Open · doi:10.1007/s41669-024-00520-8 · Cited by 3
Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure
Imprialos, K. P., Stavropoulos, K., & Papademetriou, V. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.06.004 · Cited by 3
Nicolau, J. C., Brieger, D. B., Owen, R., Furtado, R. H. M., Goodman, S. G., Cohen, M. G., Simon, T., Westermann, D., Granger, C. B., Grieve, R., et al. (2020) · Clinical Cardiology · doi:10.1002/clc.23476 · Cited by 3
Berezin, A. Е. (2015) · International Archives of Endocrinology Clinical Research · doi:10.23937/2572-407x.1510002 · Cited by 3
Kobalava, Z. D., & Kiyakbaev, G. (2018) · Kardiologiia · doi:10.18087/cardio.2018.1.10082 · Cited by 3
Goel, R., Cao, D., Chandiramani, R., Roumeliotis, A., Blum, M., Bhatt, D. L., Angiolillo, D. J., Ge, J., Seth, A., Saito, S., et al. (2020) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.29314 · Cited by 3
Self-citationWittbrodt, E. T., Bhalla, N. P., Sundell, K. A., Hunt, P. R., Wong, N. D., Kuster, M., & Mellström, C. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107859 · Cited by 3
Hypertension Treatment in Diabetes
Bensimhon, H. F., & Cavender, M. A. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.06.008 · Cited by 3
Self-citationCavender, M. A., & Kosiborod, M. (2017) · Circulation · doi:10.1161/circulationaha.117.032198 · Cited by 3
Self-citationMindfulness-based interventions for adults with type 2 diabetes mellitus
Ee, C. C., Armour, M., Piya, M. K., McMorrow, R., Al-Kanini, I., & Sabag, A. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014881 · Cited by 2
Su, W., Tai, S., Huang, Y., Hu, X., Zhou, S., & Fang, Z. (2022) · PubMed Central · doi:10.11817/j.issn.1672-7347.2022.210357 · Cited by 2
Volatile Organic Gaseous Compound Biomarkers for Cardiovascular Diseases: A Review
Kar, D., Mandal, S. K. D., & Bhattacharyya, T. K. (2024) · International Conference on Innovations and Challenges in Emerging Technologies (ICICET) · doi:10.1109/icicet59348.2024.10616368 · Cited by 2
Zhang, K., Huang, C., Li, J., Mai, P., Xu, S., Huang, F., He, W., Zhang, H., Liu, Y., & Feng, W. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100952 · Cited by 2
Omurzakova, U., Breidert, M., Donner, M. G., Toktogulova, N. A., Moldobaeva, M. S., Quartier, A., & Eftekhari, P. (2025) · Hormone and Metabolic Research · doi:10.1055/a-2716-7109 · Cited by 2
Diabetes and Cardiovascular Disease
Tahir, K. S., & Cavender, M. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-55994-0_49 · Cited by 2
Self-citationChonko, K., Russo‐Alvarez, G., Isaacs, D. M., Wang, L., & Soric, A. (2023) · INNOVATIONS in pharmacy · doi:10.24926/iip.v14i2.5456 · Cited by 5
Rethinking the Impact and Management of Diabetes in Heart Failure Patients
Schütt, K. S. (2023) · Current Heart Failure Reports · doi:10.1007/s11897-023-00633-x · Cited by 2
Pure Sensory Thalamic Stroke Presenting As Hemiballismus: A Case Report
King, B., Jamil, H., Dekhne, A., Bajwa, D., Nolte, J., FERGUSON, P. W., & Inam, S. H. A. (2024) · Cureus · doi:10.7759/cureus.68708 · Cited by 2
How Can We Increase the Utilization of Evidence-Based Medication After Myocardial Infarction?
Cavender, M. A., & Smith, S. C. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.47075 · Cited by 2
Self-citationDiabète et insuffisance cardiaque : données épidémiologiques et implications thérapeutiques.
Michel Komajda, N. (2018) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30256-0 · Cited by 2
Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
Pietraszek, A. (2020) · Current Drug Safety · doi:10.2174/1574886315666200902154736 · Cited by 2
Abtan, J., Bhatt, D. L., Elbez, Y., Ducrocq, G., Goto, S., Smith, S. C., Ohman, E. M., Eagle, K. A., Fox, K. M., Harrington, R. A., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.10.132 · Cited by 2
Self-citationSheikh, A. M., Sheikh, A., Alhozali, A. M., & Alshaikhi, S. A. (2023) · Cureus · doi:10.7759/cureus.44133 · Cited by 2
Jackson, M., Austin, D., Kwok, C. S., Rashid, M. O., Kontopantelis, E., Ludman, P., de Belder, M., Mamas, M. A., & Zaman, A. (2018) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.27642 · Cited by 2
Heart failure in diabetes: From an increased risk to a treatment target
Standl, E. (2018) · Diabetes Mellitus · doi:10.14341/dm9846 · Cited by 2
Sharma, A., Wu, J., Xu, H., Hernandez, A. F., Felker, G. M., Al‐Khatib, S. M., Green, J., Matsouaka, R., Fonarow, G. C., Singh, J. P., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.012405 · Cited by 2
Serik, S. A., Mavrycheva, N., & Bondar, T. М. (2022) · Zaporozhye Medical Journal · doi:10.14739/2310-1210.2022.5.257413 · Cited by 2
Nguyên, T. N., Nguyễn, V., & Chi, L. V. (2023) · Acta Informatica Medica · doi:10.5455/aim.2023.31.216-221 · Cited by 1
Zhuravleva, M. V., Gagarina, J. V., & Marin, T. V. (2024) · Diabetes Mellitus · doi:10.14341/dm13147 · Cited by 1
Filimonov, E., Korotenko, O., & Rumpel, O. (2025) · Hygiene and Sanitation · doi:10.47470/0016-9900-2025-104-4-422-428 · Cited by 1
Baptista, S. B., de Morais, G. P., Morais, L. A., Costa, J., Vinhas, H., Campos, G., Ferreira, P. C., Vale, N. C., Seixo, F., Santos, M. B., et al. (2025) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2025.03.006 · Cited by 1
Alnuaimi, N. S., Lößlein, L., Mousa, M., Khader, T. A., Alkhaaldi, A., Azzam, S. K., Craenenbroeck, A. H. V., Ashraf, S. M., Carmeliet, P., & AlSafar, H. S. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03187-z · Cited by 1
Influence of Race in the Association of Diabetes and Heart Failure
Lu, H.-T., bin Nordin, R., & Rahim, A. A. B. A. (2017) · US Cardiology Review · doi:10.15420/usc.2017:24:2 · Cited by 1
Baldia, P. H., Marx, N., & Schütt, K. A. (2020) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1117-8446 · Cited by 1
Kuznetsov, A. A., & Mal, G. S. (2022) · Regional blood circulation and microcirculation · doi:10.24884/1682-6655-2022-21-2-16-25 · Cited by 1
Metadata
- Authors
- Cavender, M. A., Steg, P. G., Smith, S. C., Eagle, K., Ohman, E. M., Goto, S., Kuder, J., Im, K., Wilson, P. W. F., & Bhatt, D. L.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- From TIMI Study Group, Brigham and Women’s Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA (M.A.C., J.K., K.I., D.L.B.); French Alliance for Cardiovascular Clinical Trials, Département Hospitalo-Universitaire, Fibrosis, Inflammation, Remodeling, Université Paris-Diderot, Sorbonne Paris-Cité, Laboratory of Vascular Translational Science, INSERM U-1148, Hôpital Bichat, Hopitaux Universitaires Paris-Nord Val de Seine, Assistance Publique–Hôpitaux de Paris, Paris, France (P.G.S.);...
- ORCID
- Venue
- Circulation
- Published
- 2015-09-08
- Volume
- 132
- Issue
- 10
- Pages
- 923-931
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2154038775
- Cited by
- 501
- References
- 36
- Citations by year
- 2026: 11 · 2025: 19 · 2024: 43 · 2023: 51 · 2022: 75 · 2021: 61 · 2020: 80 · 2019: 56 · 2018: 49 · 2017: 34 · 2016: 17 · 2015: 4
- FWCI
- 30.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- diabetes mellitus, heart failure hospitalization, cardiovascular events, cardiovascular mortality, myocardial infarction, stroke, heart failure with reduced ejection fraction, risk factors, REACH registry, atherothrombosis, long-term outcomes, comorbidity burden, mortality risk stratification, heart failure with preserved ejection fraction
- MeSH terms
- Aged, Diabetes Mellitus, Female, Follow-Up Studies, Health Status, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Mortality, Prospective Studies, Registries, Thrombosis, Time Factors, Cohort Studies, Treatment Outcome, Internationality, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review